Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - JUNIPER PHARMACEUTICALS INC | d572113dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2013
COLUMBIA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-10352 | 59-2758596 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 4 Liberty Square Fourth Floor Boston, Massachusetts |
02109 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 639-1500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On July 26, 2013, Columbia Laboratories, Inc. (the “Company”) issued a press release entitled “Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split” (the “Press Release”), announcing that the Board of Directors of the Company (the “Board”) set a ratio of 1-for-8 for a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and an anticipated effective date for the Reverse Stock Split of the later of (i) the filing of a certificate of amendment with respect to the Reverse Stock Split or (ii) August 9, 2013 (the “Effective Date”). A copy of the Press Release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press Release dated July 26, 2013, entitled “Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split.” | |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COLUMBIA LABORATORIES, INC. | ||||
| By: | /s/ Jonathan Lloyd Jones | |||
| Name: | Jonathan Lloyd Jones | |||
| Title: | Vice President & Chief Financial Officer | |||
Date: July 26, 2013